📊 TOVX Key Takeaways
Is Theriva Biologics, Inc. (TOVX) a Good Investment?
Theriva Biologics is a cash-burning pre-revenue biotech company with minimal commercial traction ($300K revenue) and operating losses exceeding -$2.1M, resulting in a -681% net margin. With annual cash burn of $2.5M against a cash balance of $14.4M, the company faces critical runway constraints and no clear path to profitability based on current fundamentals.
Why Buy Theriva Biologics, Inc. Stock? TOVX Key Strengths
- Low leverage (0.11x debt-to-equity) limits financial distress risk
- Adequate short-term liquidity (1.63x current ratio) provides near-term stability
- Cash position of $14.4M provides ~5.7 years of runway at current burn rate
TOVX Stock Risks: Theriva Biologics, Inc. Investment Risks
- Severe revenue shortfall ($300K annually) with no meaningful commercialization
- Negative operating cash flow of -$2.5M indicates company is burning cash to fund operations
- Massive operating losses (-709% margin) with no demonstrated path to breakeven
- Limited cash runway relative to typical biotech development timelines
- Zero insider transactions in past 90 days suggests low internal confidence
- Company is likely pre-revenue stage biotech with binary outcome risk
Key Metrics to Watch
- Operating cash burn rate and cash runway remaining
- Revenue growth trajectory and commercialization milestones
- Operating margin progress toward breakeven
- Clinical trial progress and pipeline advancement
- Capital raising activity or dilution events
Theriva Biologics, Inc. (TOVX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Theriva Biologics, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
TOVX Profit Margin, ROE & Profitability Analysis
TOVX vs Healthcare Sector: How Theriva Biologics, Inc. Compares
How Theriva Biologics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Theriva Biologics, Inc. Stock Overvalued? TOVX Valuation Analysis 2026
Based on fundamental analysis, Theriva Biologics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Theriva Biologics, Inc. Balance Sheet: TOVX Debt, Cash & Liquidity
TOVX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Theriva Biologics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-19.03 indicates the company is currently unprofitable.
TOVX Revenue Growth, EPS Growth & YoY Performance
TOVX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $300.0K | -$2.0M | $-0.05 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Theriva Biologics, Inc. Dividends, Buybacks & Capital Allocation
TOVX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Theriva Biologics, Inc. (CIK: 0000894158)
📋 Recent SEC Filings
❓ Frequently Asked Questions about TOVX
What is the AI rating for TOVX?
Theriva Biologics, Inc. (TOVX) has an AI rating of STRONG SELL with 88% confidence, based on fundamental analysis of SEC EDGAR filings.
What are TOVX's key strengths?
Claude: Low leverage (0.11x debt-to-equity) limits financial distress risk. Adequate short-term liquidity (1.63x current ratio) provides near-term stability.
What are the risks of investing in TOVX?
Claude: Severe revenue shortfall ($300K annually) with no meaningful commercialization. Negative operating cash flow of -$2.5M indicates company is burning cash to fund operations.
What is TOVX's revenue and growth?
Theriva Biologics, Inc. reported revenue of $300.0K.
Does TOVX pay dividends?
Theriva Biologics, Inc. does not currently pay dividends.
Where can I find TOVX SEC filings?
Official SEC filings for Theriva Biologics, Inc. (CIK: 0000894158) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is TOVX's EPS?
Theriva Biologics, Inc. has a diluted EPS of $-0.05.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is TOVX a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Theriva Biologics, Inc. has a STRONG SELL rating with 88% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is TOVX stock overvalued or undervalued?
Valuation metrics for TOVX: ROE of -13.3% (sector avg: 15%), net margin of -681.3% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy TOVX stock in 2026?
Our dual AI analysis gives Theriva Biologics, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is TOVX's free cash flow?
Theriva Biologics, Inc.'s operating cash flow is $-2.5M, with capital expenditures of $35.0K. FCF margin is -830.3%.
How does TOVX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -681.3% (avg: 12%), ROE -13.3% (avg: 15%), current ratio 1.63 (avg: 2).